Results 111 to 120 of about 328,284 (237)

Pure Red Cell Aplasia as an Isolated Paraneoplastic Manifestation of Thymoma: A Case Report and Literature Review

open access: yesClinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Thymomas are epithelial tumors of the anterior mediastinum and are frequently associated with paraneoplastic autoimmune disorders. Pure red cell aplasia (PRCA) is a rare but clinically significant complication, caused by immune‐mediated suppression of erythropoiesis.
Heba Amer   +8 more
wiley   +1 more source

Tacrolimus as Single‐Agent Immunotherapy for Adult‐Onset Myasthenia Gravis: Remission, Relapse, and Safety

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
Tacrolimus monotherapy yields high remission in adult‐onset MG, especially in new‐onset or younger patients. Relapse is linked to low tacrolimus concentration and rapid tapering. Hyperglycemia was the most common ADR. Long‐term use may increase cancer risk.
Zhangyan Geng   +16 more
wiley   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin   +14 more
wiley   +1 more source

Thymoma masquerading as transfusion dependent anemia

open access: yesIndian Journal of Medical and Paediatric Oncology, 2016
Pure red cell aplasia (PRCA) is a known entity in clinical medicine. Patients are often transfusion dependent for their whole life. Ascertaining its etiology is always a herculean task.
Javvid Muzamil   +5 more
doaj   +1 more source

Increased Prevalence of Extrathymic Neoplasms in Myasthenia Gravis Patients‐A Population‐Based, Matched Case–Control Study

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 1016-1024, June 2026.
ABSTRACT Introduction/Aims Myasthenia gravis (MG) is associated with thymic neoplasms. However, an increased prevalence of extrathymic neoplasms has also been reported. This study aimed to evaluate the rates of malignancy in MG patients while accounting for risk factors such as disease characteristics and immunomodulatory treatments.
Keshet Pardo   +13 more
wiley   +1 more source

Long-term prognosis in patients with thymoma combined with myasthenia gravis: a propensity score-matching analysis

open access: yesFrontiers in Medicine
IntroductionWe aimed to assess the impact of myasthenia gravis (MG) on the long-term prognosis in patients with thymoma after surgery and identify related prognostic factors or predictors.MethodsThis retrospective observational study included 509 ...
Kai Zhao   +11 more
doaj   +1 more source

The Effect of Thymectomy on the Incidence of Extrathymic Cancers and Autoimmune Diseases in Patients With Non‐Thymomatous Myasthenia Gravis

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 1065-1072, June 2026.
ABSTRACT Introduction/Aims Thymectomy is associated with positive effects on myasthenia gravis (MG), but there is conflicting evidence regarding potential deleterious long‐term outcomes, such as increased cancer and autoimmune disease risk. We aimed to assess these outcomes in thymectomized versus non‐thymectomized MG patients.
Mohamed Khateb   +3 more
wiley   +1 more source

Giant thymoma - case report. [PDF]

open access: yes, 2014
Efst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinnÆxli í hóstarkirtli eru yfirleitt góðkynja og staðsett í framanverðu miðmæti.
Elín Maríusdóttir   +3 more
core  

Somatic Mutations in Acquired Pure Red Cell Aplasia: Incidence and Implications

open access: yes
American Journal of Hematology, Volume 101, Issue 7, Page 1554-1555, July 2026.
Robert T. Means Jr
wiley   +1 more source

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

open access: yesMuscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy